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IP200 (focal adhesion kinase [FAK] family inter-
acting protein of 200 kD) is a newly identiﬁed protein
that binds to the kinase domain of FAK and inhibits
its kinase activity and associated cellular functions. Here,
we identify an interaction between FIP200 and the
TSC1–TSC2 complex through FIP200 binding to TSC1.
We found that association of FIP200 with the TSC1–
TSC2 complex correlated with its ability to increase cell
size and up-regulate S6 kinase phosphorylation but was
not involved in the regulation of cell cycle progression.
Conversely, knockdown of endogenous FIP200 by RNA
F
 
interference reduced S6 kinase phosphorylation and cell
size, which required TSC1 but was independent of FAK.
Furthermore, overexpression of FIP200 reduced TSC1–
TSC2 complex formation, although knockdown of en-
dogenous FIP200 by RNA interference did not affect
TSC1–TSC2 complex formation. Lastly, we showed that
FIP200 is important in nutrient stimulation-induced, but
not energy- or serum-induced, S6 kinase activation.
Together, these results suggest a cellular function of
FIP200 in the regulation of cell size by interaction with
the TSC1–TSC2 complex.
 
Introduction
 
FIP200 (FAK family interacting protein of 200 kD) is a newly
identified protein inhibitor for FAK and its related kinase Pyk2
(Ueda et al., 2000; Abbi et al., 2002). It is a 1,591-aa protein
with a large coiled-coil region (residues 860–1391) containing
a leucine zipper motif (residues 1371–1391). FIP200 is a con-
served protein present in human, mouse, rat, 
 
Xenopus laevis,
 
and 
 
Drosophila melanogaster
 
. Like FAK, FIP200 is widely ex-
pressed in various human tissues. FIP200 gene localizes in
8q11 chromosome (Chano et al., 2002b), containing several
loci of putative tumor suppressor genes, and loss of hetero-
zygosity for this region has been associated with breast cancer
(Dahiya et al., 1998). We recently showed that association of
endogenous FIP200 with FAK correlated with FAK inactiva-
tion upon cell detachment. Overexpression of FIP200 inhibited
FAK kinase activity and autophosphorylation as well as its
associated cellular functions including cell spreading, cell
migration, and cell cycle progression. Conversely, disruption
of the functional interaction between endogenous FIP200 with
FAK led to increased FAK phosphorylation and partial restor-
ation of cell cycle progression in cells plated on poly-
 
L
 
-lysine.
These results identify FIP200 as a novel protein inhibitor for
FAK (Abbi et al., 2002).
FIP200 is also identified by Chano et al. (2002a) inde-
pendently as a potential regulator of the RB1 gene (designated
by this group as RB1CC1 for RB1-inducible coiled-coil 1, but
will be referred to here as FIP200 for convenience). The
expression levels of FIP200 correlated with those of RB1 in vari-
ous cancer cell lines and normal human tissues. In addition,
FIP200 and RB1 are preferentially coexpressed and contrib-
uted to the maturation of human embryonic musculoskeletal
cells and may regulate the proliferative activity and maturation
of tumor cells derived from these tissues (Chano et al., 2002d).
Lastly, it was found that 20% of primary breast cancers that
were screened contained large deletion mutations in FIP200
that are predicted to generate markedly truncated proteins
(Chano et al., 2002c). These studies are consistent with our
findings showing negative regulation of cell cycle progression
by FIP200 (Abbi et al., 2002).
 
TSC1
 
 and 
 
TSC2
 
 (or hamartin and tuberin, respectively)
are both tumor suppressor genes and mutation in either gene
causes tuberous sclerosis (TSC) that occurs in 
 
 
 
1 in 6,000 of
the population and is defined by the formation of hamartomas
in a wide range of tissues. Both TSC1 and TSC2 have coiled-
coil regions and they exist as heterodimers (Plank et al., 1998;
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van Slegtenhorst et al., 1998; Kwiatkowski, 2003). Although
TSC1 has no known enzymatic activity, TSC2 contains a
COOH-terminal GAP domain for the small G protein Rheb
(Garami et al., 2003; Inoki et al., 2003a; Saucedo et al., 2003;
Stocker et al., 2003; Tee et al., 2003; Y. Zhang et al., 2003).
Recent studies have indicated that the TSC1–TSC2 complex
regulates cellular functions mainly by their inhibition of mTOR
and its targets S6 kinase (S6K) and 4E-BP1 (Potter et al., 2001;
Tapon et al., 2001; Gao et al., 2002; Goncharova et al., 2002;
Inoki et al., 2002; Manning et al., 2002; Tee et al., 2003). In-
creased S6K activity is observed in TSC mutations in 
 
D. mela-
nogaster
 
, cells derived from TSC1 or TSC2 knockout mice, or
cells treated with TSC1 or TSC2 small interfering RNA. Con-
sistent with its function as a negative regulator of mTOR and
its targets, the TSC complex has been found to regulate various
cellular functions such as cell cycle progression, cell size con-
trol, cell survival, and apoptosis (Hengstschlager et al., 2001;
Inoki et al., 2003b; Shamji et al., 2003).
To investigate the molecular mechanisms by which
FIP200 regulates intracellular signaling pathways and cellular
functions, we used yeast two-hybrid screening to identify other
proteins that interact with FIP200. Here, we report identifica-
tion of FIP200 interaction with the TSC1–TSC2 complex and
show that this interaction leads to inhibition of TSC1–TSC2
complex function resulting in increased S6K activity and cell
growth. These studies suggest a novel function for FIP200 in
the regulation of cell size control in addition to its functioning
as an inhibitor for FAK and regulator of RB1 expression.
 
Results
 
Identification of FIP200 interaction with 
TSC1
 
To understand the mechanisms and potential role of FIP200 in
signal transduction and regulation of cellular functions, we used
the yeast two-hybrid screen to identify cellular proteins that in-
teract with FIP200. Because the full-length FIP200 and its
COOH-terminal part (containing the large coiled-coil region)
showed strong autoactivation in the yeast two-hybrid system
(unpublished data), we used the NH
 
2
 
-terminal half of FIP200
(residues 1–859, designated as N1-859 here) as the bait. Screen-
ing 
 
 
 
1 
 
 
 
 10
 
6
 
 clones of a human heart library yielded several
clones that specifically interacted with N1-859. Partial sequenc-
ing of the clones indicated that two clones (#16 and #34) encode
a fragment of TSC1 (residues 304–1165; Fig. 1 A) and one
(clone #16) was further analyzed. The interaction was confirmed
by cotransforming yeast cells with the recovered prey plasmid
pB42AD-#16 and pLexA-N1-859, pLexA, or pLexA-Lamin C
encoding the irrelevant protein Lamin C as controls. We found
that clone #16 interacted specifically with N1-859, but not with
control Lamin C or the empty vector, in the yeast.
We next examined potential interaction of FIP200 with
TSC1 in 293T cells. The insert from pB42AD-#16 was excised
and cloned into a mammalian expression vector with Myc tag.
The resulting vector encoding Myc-tagged TSC1 304–1165
was cotransfected into 293T cells along with pKH3-FIP200 en-
coding the HA-tagged FIP200. Cell lysates were immunopre-
cipitated with anti-HA antibody and followed by Western
blotting with anti-Myc antibody. Fig. 1 B shows that Myc-
TSC1 304–1165 (i.e., clone #16) was coprecipitated with HA-
FIP200, but not detected in the immunoprecipitates of control
lysates from cells cotransfected with pKH3 empty vector. Ad-
ditional experiments using Myc-tagged full-length TSC1 and
several segments indicated that FIP200 could interact with
TSC1, its 403–787-aa region, but not with TSC1 1–402 and
789–1165 aa regions. We also detect the interaction of the
FIP200 N1-859 fragment with TSC1 403–787 aa and full-
length TSC1 (not depicted). Lastly, we found that recombinant
Figure 1. Interaction of FIP200 with TSC1. (A) Schematic diagram show-
ing the region of FIP200 used as the bait for yeast two-hybrid screen and
TSC1 prey and other segments used for binding studies. (B) 293T cells
were cotransfected with vectors encoding the HA-FIP200 or vector control
and plasmids encoding Myc-tagged TSC1 304–1165 aa (clone 16),
other TSC1 segments, or full-length TSC1, as indicated. Cell lysates were
immunoprecipitated with anti-HA and analyzed by Western blotting with
anti-Myc to detect bound TSC1 segments. Aliquots of the lysates (WCL)
were also analyzed directly by Western blotting with anti-Myc. (C) Puri-
fied GST-TSC1M was incubated with immobilized MBP fusion proteins
containing the FIP200 N1-859 segment or MBP alone. The bound pro-
teins along with an aliquot of input were resolved on SDS-PAGE and ana-
lyzed by Western blotting with anti-GST (top). The membrane was also
stained with Ponceau S (bottom). (D) 293T cells were cotransfected with
vectors encoding HA-FIP200 or vector control and plasmids encoding
Myc-TSC1 and GST-TSC2. Aliquots of the lysates (WCL) or anti-HA immuno-
precipitates from the lysates (IP: HA) were analyzed by Western blotting
with anti-Myc, anti-GST, or anti-HA, as indicated. (E) Lysates prepared
from 293T cells were immunoprecipitated by anti-FIP200, anti-TSC2, and
anti-TSC1 to precipitate respective endogenous proteins or HA antibody
as a control. They were then analyzed by Western blotting with anti-TSC2
(top), anti-FIP200 (middle), or anti-TSC1 (bottom) to detect the associated
proteins. (F) Lysates from MEFs were immunoprecipitated by anti-TSC1 or
anti-vinculin. They were then analyzed by Western blotting with anti-
FIP200 (top) or anti-TSC1 (bottom). (E and F) Aliquots of the lysates (WCL)
were also analyzed directly. 
FIP200 INTERACTION WITH TSC1–TSC2 AND CELL SIZE REGULATION • GAN ET AL.
 
381
 
GST fusion protein containing TSC1 residues 403–787 bound
to purified MBP fusion protein containing FIP200 N1-859, but
not MBP alone, in vitro, suggesting a direct interaction be-
tween FIP200 and TSC1 (Fig. 1 C). Together, these results
identify TSC1 as a FIP200 interacting protein and suggest that
the interaction is mediated by the FIP200 1–859 aa region and
the TSC1 403–787 aa region.
 
Association of FIP200 with the TSC1–
TSC2 complex
 
TSC1 and TSC2 have been shown to function as a complex in
vivo (Plank et al., 1998; van Slegtenhorst et al., 1998; Kwiat-
kowski, 2003). Therefore, we tested whether FIP200 could as-
sociate with the TSC1–TSC2 complex in cells. pKH3-FIP200
was cotransfected into 293T cells with plasmids encoding
Myc-TSC1 and GST-TSC2. Lysates were prepared from the
transfected cells and immunoprecipitated by anti-HA, and the
associated proteins were analyzed by Western blotting by re-
spective antibodies. Fig. 1 D shows that both TSC1 and TSC2
were coprecipitated with FIP200, but not in pKH3 control vec-
tor–transfected cells. Consistent with these transfection studies,
we could also detect the interaction of endogenous FIP200 with
the endogenous TSC1–TSC2 complex in 293T cells (Fig. 1 E).
Both TSC1 and TSC2 were found in anti-FIP200 immunopre-
cipitates, but not in the control immunoprecipitates with an ir-
relevant antibody anti-HA. Likewise, FIP200 is also detected
in both anti-TSC1 and -TSC2 immunoprecipitates, but not con-
trol immunoprecipitates. Lastly, coimmunoprecipitation of en-
dogenous FIP200 with TSC1, but not vinculin, was also ob-
served in mouse embryonic fibroblasts (MEFs; Fig. 1 F).
Together, these results demonstrate that FIP200 could associate
with the TSC1–TSC2 complex in mammalian cells such as
293T cells and MEFs.
 
FIP200 interaction with the TSC1–TSC2 
complex is not involved in FIP200 
regulation of cell cycle progression
 
Our previous studies showed that FIP200 plays an important
role in the regulation of cell cycle progression (Abbi et al.,
2002). Some studies also showed that the TSC1–TSC2 com-
plex is capable of regulating cell proliferation (Soucek et al.,
1998, 2001; Miloloza et al., 2000; Hengstschlager and Rosner,
2003). Thus, the identification of the interaction between
FIP200 and the TSC1–TSC2 complex raises the possibility that
this interaction may play a role in the regulation of cell cycle
progression by FIP200. Indeed, the FIP200 N1-859 fragment,
which can interact with the TSC1–TSC2 complex (Fig. 2 A),
showed similar activity as the full-length FIP200 in the inhibi-
tion of cell cycle progression as measured by BrdU incorpora-
tion (not depicted). However, the smaller segment of FIP200
(N1-638; Fig. 1 A), which did not associate with the TSC1–
TSC2 complex (Fig. 2 A), could also inhibit cell cycle progres-
sion (Abbi et al., 2002). These results suggest that FIP200 in-
teraction with the TSC1–TSC2 complex might not be required
for FIP200 regulation of cell cycle progression.
To further evaluate the role of the TSC1–TSC2 complex
in cell cycle inhibition by FIP200, we examined the effects of
FIP200 on cell cycle progression in TSC1-null fibroblasts de-
rived from TSC1 knockout mice (Kwiatkowski et al., 2002).
Cells were transiently transfected with pKH3-FIP200 or the
control pKH3-Grb7 plasmid, and then serum-stimulated cell
cycle progression was measured by BrdU incorporation assay
as described previously (Zhao et al., 1998; Abbi et al., 2002).
We observed that TSC1
 
 
 
/
 
 
 
 MEFs exhibited increased rate of
cell cycle progression compared with TSC1
 
 
 
/
 
 
 
 MEF or NIH
3T3 cells (Fig. 2 B). Nevertheless, FIP200 significantly inhib-
ited BrdU incorporation in TSC1
 
 
 
/
 
 
 
 MEFs as well as in
TSC1
 
 
 
/
 
 
 
 MEF and NIH 3T3 cells, when compared with the
control plasmid. Together, these data suggest that FIP200 inter-
action with the TSC1–TSC2 complex is not required for
FIP200 regulation of cell cycle progression.
 
FIP200 function in cell size control
 
Recent studies have identified the TSC1–TSC2 complex as a
key regulator of cell size control (Inoki et al., 2003b; Shamji et
al., 2003). Therefore our identification of the interaction be-
tween FIP200 and the TSC1–TSC2 complex raises the interest-
ing possibility that FIP200 may regulate cell size through in-
teraction with the TSC1–TSC2 complex. To investigate this
possibility directly, 293T cells were transiently transfected
with an expression vector encoding FIP200 or an empty vector
control and the effects on cell size were then measured by de-
termining the mean forward scatter (mean FSC-H) with a flow
cytometer. Fig. 3 A shows that overexpression of FIP200 in
these cells led to a right-shift of the mean FSC-H distribution
compared with the empty vector–transfected cells, which cor-
responds to an increase in the size of the FIP200-transfected
populations of cells. Quantification of the data indicated an
 
 
 
5% increase in the average cell size in the FIP200-transfected
293T cells (Fig. 3 B). This is likely to be an underestimation of
Figure 2. FIP200 interaction with the TSC1–TSC2 complex is not required
for FIP200 regulation of cell cycle progression. (A) 293T cells were
cotransfected with vectors encoding HA-N1-859 or HA-N1-638 or vector
control and plasmids encoding Myc-TSC1 and GST-TSC2. Aliquots of the
lysates (WCL) or anti-HA immunoprecipitates from the lysates (IP: HA)
were analyzed by Western blotting with anti-Myc, anti-GST, or anti-HA,
as indicated. (B) NIH 3T3, TSC1 / , or TSC1 /  fibroblasts were tran-
siently transfected with pKH3-FIP200 or pKH3-Grb7 control. They were
then analyzed for BrdU incorporation as described previously (Zhao et
al., 1998). The percentage of BrdU ( )/positively transfected cells (as
identified by anti-HA staining) was determined by analyzing  100 posi-
tively transfected cells for each transfection in multiple fields. The results
show mean   SEM for at least three independent experiments. 
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the FIP200 effect on cell size as the transfection efficiency is
 
 
 
100% for these cells. Similar studies indicated that the N1-
859 segment of FIP200, but not the N1-638 segment, which
does not bind to TSC1–TSC2, also increased the average cell
size of the transfected 293T cells (Fig. 3, A and B). Further-
more, the increase in cell size was observed in 293T cells in ei-
ther G1 or G2/M phase (Fig. 3 C). Together, these results sug-
gested a novel function for FIP200 in the regulation of cell size,
possibly through its interaction with the TSC1–TSC2 complex.
 
FIP200 regulation of S6K 
phosphorylation through its association 
with the TSC1–TSC2 complex
 
Recent studies have shown that the TSC1–TSC2 complex neg-
atively regulates cell size through inhibition of the mTOR–S6K
pathway (Garami et al., 2003; Inoki et al., 2003a; Saucedo et
al., 2003; Stocker et al., 2003; Tee et al., 2003; Y. Zhang et
al.,  2003). Therefore, we examined the possible effect of
FIP200 on TSC1–TSC2 complex–mediated inhibition of S6K
to determine the mechanisms by which FIP200 interaction
with the TSC1–TSC2 complex regulated cell size. 293T cells
were cotransfected with pKH3-FIP200 encoding HA-FIP200 or
pKH3 empty vector along with plasmids encoding Myc-TSC1,
GST-TSC2, and HA-tagged S6K. Cell lysates were then pre-
pared and analyzed by Western blotting with anti-Thr389 phos-
phorylated S6K to determine its activation state or anti-S6K to
verify similar expression levels of the protein in all samples.
Consistent with previous observations (Inoki et al., 2002,
2003b), overexpression of TSC1 and TSC2 decreased S6K
phosphorylation at Thr389 (Fig. 4 A, compare lanes 1 and 3).
Interestingly, coexpression of FIP200 reversed the inhibition of
S6K phosphorylation by the TSC1–TSC2 complex (Fig. 4 A,
compare lane 4 with lanes 1 and 3). We also observed that
overexpression of FIP200 alone increased S6K phosphory-
lation, possibly through its interaction with the endogenous
TSC1–TSC2 complex (Fig. 4 A, compare lanes 1 and 2). Simi-
larly, expression of FIP200 reversed inhibition of endogenous
S6K phosphorylation by overexpression of the TSC1–TSC2
complex (Fig. 4 B, left) and expression of FIP200 alone also
increased endogenous S6K phosphorylation (Fig. 4 B, right). It
should be noted that the effects of FIP200 (and TSC also) on
Figure 3. FIP200 function in cell size control. (A) 293T cells were trans-
fected with vectors encoding HA-FIP200, HA-N1-859, HA-N1-638, or
empty vector control. The cells were analyzed by FACS to determine cell
size, as described in Materials and methods. Shown are histograms of
mean FSC-H comparing cells transfected with FIP200 or its segments (gray
lines) with cells transfected with the empty vector. Note that a right-shift of
the mean FSC-H distribution reflects cell size increase. (B) Comparison of
average size of cells transfected with FIP200 or its segments, as indicated.
The results are normalized to cells transfected with empty vector and show
relative mean FSC-H   SD for three independent experiments (*, P  
0.001 vs. control). (C) Histograms of mean FSC-H comparing cells trans-
fected with FIP200 (gray lines) with cells transfected by the empty vector in
G1 (top) and G2/M (bottom) phase population.
Figure 4. Function of FIP200 association with TSC1–TSC2 in the regulation
of S6K and 4EBP-1 phosphorylation. (A–C) 293T cells were cotransfected
with vectors encoding Myc-TSC1 and GST-TSC2 or empty vector control,
HA-FIP200 (A and B), HA-N1-859 or HA-N1-638 (C), and HA-tagged
S6K reporter plasmid (A and C), as indicated. 2 d after transfection, cell
lysates were prepared and analyzed by Western blotting with anti-
pS6K(T389) to detect activated HA-S6K reporter (A and C) or endoge-
nous S6K (B) and other antibodies to verify expression levels of respective
proteins, as indicated. Activated HA-S6K is normalized to the expression
levels of HA-S6K in A and C and mean   SD for three independent exper-
iments are shown on the bottom. (D) 293T cells were cotransfected with
vectors encoding HA-FIP200, HA-N1-859, HA-N1-638, or empty vector
control along with a Flag-tagged 4EBP-1 reporter plasmid. 2 d after trans-
fection, cell lysates were immunoprecipitated by anti-Flag and analyzed
by Western blotting with anti-p4EBP-1(S65) to detect activated Flag-4EBP-1
reporter (top) or anti-Flag to detect Flag-4EBP-1 expression levels (middle).
Aliquots of lysates were also analyzed directly by Western blotting with
anti-HA to verify expression levels of HA-FIP200 and its fragments (bottom). 
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endogenous S6K phosphorylation appears to be less pro-
nounced than that using the transfected HA-S6K as a reporter.
This is probably due to the 
 
 
 
100% transfection efficiency in
these cells. Furthermore, we found that overexpression of
FIP200 N1-859, but not N1-638, fragment also increased S6K
phosphorylation and reversed inhibition of S6K phosphoryla-
tion by the TSC1–TSC2 complex when coexpressed with
TSC1 and TSC2 (Fig. 4 C). Consistent with the results on S6K
phosphorylation, we also found that FIP200 and its fragment
N1-859, but not N1-638 fragment, induced phosphorylation of
4E-BP1, another target of mTOR, in 293T cells (Fig. 4 D). To-
gether, these results suggest that FIP200, through its N1-859
region association with the TSC1–TSC2 complex, may nega-
tively regulate TSC1–TSC2 complex inhibition of the mTOR–
S6K pathway, resulting in an increase in cell size.
We used RNA interference (RNAi) to test the effect of
down-regulation of endogenous FIP200 on S6K phosphoryla-
tion. We selected several RNAi-targeting sequences based on
the human FIP200 cDNA sequence and cloned them into the
RNAi vector pBS-U6 (Sui et al., 2002). One of these se-
quences (FIP200 #7), which showed the most significant
down-regulation of FIP200 expression in preliminary studies,
was used for further experiments. As shown in Fig. 5 A, trans-
fection of RNAi vector pBS-U6-FIP200 #7 into 293T cells
significantly reduced endogenous FIP200 protein level com-
pared with 293T cells transfected with either pBS-U6 empty
vector or vector pBS-U6-ctrl, which expresses an irrelevant
small interfering RNA sequence. Furthermore, it had no effect
on the expression of vinculin, suggesting specificity of the
RNAi vector for FIP200 knockdown. Interestingly, we found
that a reduction of endogenous FIP200 levels by FIP200
RNAi decreased the phosphorylation of the transfected S6K
(Fig. 5 A, compare lane 3 with 1). In contrast, transfection of
pBS-U6-ctrl did not affect S6K phosphorylation (Fig. 5 A,
compare lane 3 with 2), suggesting that the effect on S6K
phosphorylation is due to down-regulation of FIP200, but not
a nonspecific effect of the RNAi pathway itself. Similar re-
sults were also obtained in HeLa cells (not depicted). We also
found that knockdown of FIP200 by FIP200 RNAi reduced
phosphorylation of endogenous S6K and 4EBP-1 (Fig. 5 B).
Finally, we found that transfection of 293T cells with FIP200
RNAi, but not the control RNAi, reduced the size of the cells
(Fig. 5 C), which is consistent with the observation that over-
expression of FIP200 in 293T cells increased their size (Fig.
3). Together, these results provide further support for the idea
that FIP200 regulated cell size through its effect on the
TSC1–TSC2 target S6K.
 
The role of TSC1 and mTOR in the 
regulation of S6K and cell size by 
FIP200
 
To ensure that FIP200 regulation of S6K is through the TSC1–
TSC2 complex, but not other potential mechanisms (e.g., its in-
hibition of FAK [Abbi et al., 2002]), we evaluated the role of
TSC1 down-regulation on the decreased S6K phosphorylation
on down-regulation of endogenous FIP200. TSC1 RNAi vector
pBS-U6-TSC1 #3 was generated and shown to significantly
decrease endogenous TSC1 protein level in 293T cells. 293T
cells were then transfected with the FIP200 and TSC1 RNAi
vectors, either individually or in combination, and S6K phos-
phorylation was then tested. As shown in Fig. 6 A, cotransfec-
tion of pBS-U6-TSC1 #3 reversed the decrease in S6K phos-
phorylation induced by FIP200 RNAi vector pBS-U6-FIP200
#7 (compare lane 4 and lanes 1 and 2). As expected, down-reg-
ulation of TSC1 alone also increased S6K phosphorylation
(Fig. 6 A, compare lanes 1 and 3). Western blotting of the par-
allel samples showed that transfection of pBS-U6-TSC1 #3 de-
creased TSC1 expression, but had no effect on the expression
of FIP200. Likewise, transfection of pBS-U6-FIP200 #7 only
reduced expression of FIP200, but had no effect on TSC1 ex-
pression. Neither vector affected expression levels of vinculin
Figure 5. Effect of down-regulation of endogenous FIP200 by RNAi on
phosphorylation of S6K and cell size. (A and B) 293T cells were transfected
with HA-S6K and pBS-U6 empty vector, pBS-U6-ctrl or pBS-U6-FIP200 #7
(A), or just pBS-U6-ctrl or pBS-U6-FIP200 #7 (B). 3 d after transfection, cell
lysates were analyzed by Western blotting with various antibodies, as indi-
cated. (C) Histograms of mean FSC-H comparing 293T cells transfected
with pBS-U6-FIP200 #7 (FIP200 RNAi; gray lines) with cells transfected
with pBS-U6-ctrl (control RNAi). Note that a left-shift of the mean FSC-H
distribution reflects cell size decrease. Inset shows the expression level of
endogenous FIP200 (top) and control vinculin (bottom) in 293T cells trans-
fected with control RNAi (lane 1) and FIP200 RNAi (lane 2). 
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or S6K. These results demonstrate the specificity of the RNAi
vectors used in the experiments.
To complement the RNAi approach, we also examined
the effect of FIP200 on TSC1
 
 
 
/
 
 
 
 MEFs. Fig. 6 B shows that
overexpression of FIP200 increased endogenous S6K phosphor-
ylation in TSC1
 
 
 
/
 
 
 
 MEFs, but not TSC1
 
 
 
/
 
 
 
 MEFs (com-
pare lanes 1 and 2 with lanes 5 and 6). Furthermore, we found
that treatment of cells with the mTOR inhibitor rapamycin
abolished stimulation of S6K phosphorylation by FIP200 (Fig.
6 B, lanes 3 and 4). Consistent with these results, we observed
that overexpression of FIP200 in TSC1
 
 
 
/
 
 
 
 MEFs, but not
TSC1
 
 
 
/
 
 
 
 MEFs, increased cell size (Fig. 6, C and D). To-
gether, these studies suggest that FIP200 interaction with the
TSC1–TSC2 complex inhibits its function in the negative regu-
lation of S6K activation through mTOR, which is responsible
for the regulation of cell size control by FIP200.
Similar studies were performed to test a potential role of
FAK in FIP200 regulation of S6K phosphorylation because
previous studies showed that FIP200 could inhibit FAK, which
may play a role in the activation of S6K (Malik and Parsons,
1996). Interestingly, we found that down-regulation of FAK by
the RNAi vector pBS-U6-FAK #1 did not affect the reduction
of S6K phosphorylation induced by pBS-U6-FIP200 #7, al-
though it clearly down-regulated expression of FAK in these
cells (Fig. 7 A). The specificity of the vectors was also demon-
strated by analysis of parallel samples with anti-FIP200 and
anti-vinculin. Consistent with the RNAi results, we also found
that overexpression of FIP200 increased S6K phosphorylation
in both FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells (Fig. 7 B). Together,
these results suggest that FIP200 regulation of S6K phosphory-
lation is through its inhibition of the TSC1–TSC2 complex but
not FAK.
 
Regulation of TSC1–TSC2 complex 
formation by FIP200
 
Previous studies suggested that TSC1–TSC2 complex forma-
tion is critical for its function (Plank et al., 1998; van Sleg-
tenhorst et al., 1998; Kwiatkowski, 2003). Therefore, we inves-
tigated whether FIP200 could affect TSC1–TSC2 complex
formation to understand the mechanisms by which FIP200 reg-
ulates TSC1–TSC2 activity as shown in the aforementioned
studies. 293T cells were transfected with pKH3-FIP200 or
pKH3 vector as a control. TSC2 was then precipitated by anti-
TSC2 antibody and the coprecipitated TSC1 was analyzed by
Western blotting with anti-TSC1 antibody. As shown in Fig. 8
A, overexpression of FIP200, but not the control pKH3 vector,
reduced association between TSC1 and TSC2 in these cells.
Similar experiments showed that overexpression of the FIP200
N1-859 segment can also decrease TSC1–TSC2 interaction,
whereas overexpression of the N1-638 segment did not (Fig. 8
B). These results raised the possibility that FIP200 may reduce
the formation of the TSC1–TSC2 complex to negatively regu-
late its function. Surprisingly, however, knockdown of endoge-
nous FIP200 by RNAi did not affect TSC1–TSC2 complex for-
mation (or expression levels of TSC1 and TSC2; Fig. 8 C).
These results suggested that FIP200 may inhibit TSC1–TSC2
complex function through mechanisms other than disruption of
the complex formation, although we cannot exclude the possi-
Figure 6. FIP200 regulation of S6K phosphorylation and cell size requires
TSC1 and mTOR activity. (A) 293T cells were transfected with pBS-U6-
FIP200 #7 and pBS-U6-TSC1 #3, individually or in combination, as indi-
cated. 3 d after transfection, cell lysates were prepared and analyzed by
Western blotting with various antibodies, as indicated. (B–D) TSC1 / 
MEFs and control TSC1 /  MEFs were infected with recombinant adeno-
viruses encoding FIP200 (Ad-FIP200) or GFP (Ad-GFP, as control), as indi-
cated. Some samples (B, lanes 3 and 4) were treated with the mTOR in-
hibitor rapamycin (25 nM for 1 h). (B) Cell lysates were then analyzed by
Western blotting with anti-pS6K(T389), anti-S6K, or anti-FIP200. (C) Histo-
grams of mean FSC-H comparing cells infected with Ad-FIP200 (gray
lines) to cells infected with control Ad-GFP. (D) Relative mean FSC-H   SD
for three independent experiments (results are normalized to cells infected
with Ad-GFP).
Figure 7. Stimulation of S6K phosphorylation by FIP200 is independent
of FAK. (A) 293T cells were transfected with pBS-U6-FIP200 #7 and pBS-
U6-FAK #1, individually or in combination, as indicated. 3 d after trans-
fection, cell lysates were prepared and analyzed by Western blotting with
various antibodies, as indicated. (B) FAK /  and control FAK /  cells
were infected with recombinant adenoviruses encoding FIP200 (Ad-FIP200)
or GFP (Ad-GFP, as control), as indicated. Cell lysates were then analyzed
by Western blotting with anti-pS6K(T389) or anti-S6K. 
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bility that it could also function to reduce the complex forma-
tion under some conditions.
 
Potential role of FIP200 in the 
regulation of the TSC–S6K pathway by 
nutrient level
 
Recent studies show that a variety of extracellular and intra-
cellular signals such as growth factors, energy level, nutri-
ent level, and hypoxia could regulate S6K phosphorylation
through the TSC1–TSC2 complex (Gao et al., 2002; Inoki et
al., 2003b; H. Zhang et al., 2003; Brugarolas et al., 2004). To
examine a potential role of FIP200 in these signaling path-
ways, we derived FIP200
 
 
 
/
 
 
 
 MEFs from FIP200 knockout
mouse embryos (see Materials and methods). Fig. 9 A shows
the absence of FIP200 protein expression, but similar expres-
sion levels of TSC1, TSC2, and vinculin, in the FIP200
 
 
 
/
 
 
 
MEFs compared with FIP200
 
 
 
/
 
 
 
 MEFs. We then examined
the stimulation of S6K phosphorylation by various signals in
FIP200
 
 
 
/
 
 
 
 MEFs using FIP200
 
 
 
/
 
 
 
 MEFs as controls. We
found that S6K phosphorylation was induced similarly in
these two cells by serum (Fig. 9 B) and energy (Fig. 9 D)
stimulations. Interestingly, FIP200
 
 
 
/
 
 
 
 MEFs exhibited par-
tial resistance to nutrient stimulation-induced S6K phosphor-
ylation compared with the FIP200
 
 
 
/
 
 
 
 MEF controls (Fig. 9
C). Consistent with this, reduced S6 phosphorylation was
also observed in FIP200
 
 
 
/
 
 
 
 MEFs upon nutrient stimulation
compared with FIP200
 
 
 
/
 
 
 
 MEFs. To further validate these
results using FIP200
 
 
 
/
 
 
 
 MEFs, we also examined stimula-
tion of S6K phosphorylation by serum and nutrients upon
FIP200 knockdown by RNAi in 293T cells. Consistent with
results from FIP200
 
 
 
/
 
 
 
 MEFs, FIP200 knockdown had lit-
tle effect on S6K phosphorylation induced by serum (Fig. 9
E), but significantly blocked nutrient-induced S6K phosphor-
ylation (Fig. 9 F). These results suggest that FIP200 may
function in the nutrient input to the TSC1–TSC2 complex
rather than being a general component of the TSC1–TSC2 to
S6K pathway.
 
Discussion
 
Both cell proliferation and cell size control are fundamental bio-
logical processes that must be carefully orchestrated, and dys-
regulation of either can lead to diseases such as cancer. In con-
trast to our understanding of the mechanisms that control cell
proliferation, less is known about the mechanisms that control
cell size and, particularly, the mechanisms by which cell prolif-
eration and cell size are coordinately regulated. Recently, we
identified a novel protein named FIP200, which plays an impor-
tant role in the regulation of cell cycle progression (Abbi et al.,
2002). In this study, we showed that FIP200 can also regulate
cell size through interaction with the TSC1–TSC2 complex and
activation of S6K. These results identify FIP200 as a regulator
that plays roles in both cell proliferation and cell size control.
Most other proteins known to play roles in both cell pro-
liferation and cell size usually regulate these two cellular pro-
cesses in a similar manner. For example, PTEN can inhibit cell
Figure 8. Regulation of the TSC1–TSC2 complex formation by FIP200.
293T cells were transfected with HA empty vector or HA-FIP200 (A), HA-
N1-859 or HA-N1-638 (B), or pBS-U6-ctrl or pBS-U6-FIP200 #7 (C). Cell
lysates were then immunoprecipitated by anti-TSC2 followed by Western
blotting with anti-TSC1 to detected associated TSC1 or anti-TSC2 to verify
similar amount in each samples. Cell lysates were also analyzed by Western
blotting with the various antibodies indicated.
Figure 9. Role of FIP200 in nutrient stimulation-induced activation of
S6K. (A) Cell lysates from FIP200 / MEFs and control FIP200 / MEFs
were analyzed by Western blotting with anti-FIP200, anti-TSC2, anti-
TSC1, or anti-vinculin. (B) FIP200  /  and FIP200 /  MEFs were se-
rum starved overnight. They were then left untreated or treated with fresh
DME   10% FBS for the different periods of time indicated. Cell lysates
were then analyzed by Western blotting with anti-pS6K(T389) and anti-
S6K, respectively. (C and D) FIP200  /  and FIP200 /  MEFs were
pretreated with DPBS   10% FBS (C) or 50 mM 2-DG in DME   10% FBS
(D) for 60 min. They were then left untreated or retreated with fresh DME  
10% FBS for 60 min. Cell lysates were then analyzed by Western blot-
ting with anti-pS6K(T389) and anti-S6K, respectively (C and D) as well as
anti-pS6(S240/244) and anti-S6 (C). (E and F) 293T cells transfected with
pBS-U6-ctrl (control RNAi) or pBS-U6-FIP200 #7 (FIP200 RNAi) were
serum starved overnight (at 2 d after transfection; E) or pretreated with
DPBS   10% FBS for 60 min (at 3 d after transfection; F). They were then
left untreated or treated with fresh DME   10% FBS for the different periods
of time indicated. Cell lysates were then analyzed by Western blotting
with anti-pS6K(T389), anti-S6K, or anti-FIP200.JCB • VOLUME 170 • NUMBER 3 • 2005 386
proliferation and negatively regulate cell size (Groszer et al.,
2001), whereas Myc can promote cell proliferation and in-
crease cell size (Iritani and Eisenman, 1999). In contrast, our
studies indicated that FIP200 regulates cell proliferation and
cell size in a differential manner, which inhibits cell prolifera-
tion but increases cell size. Interestingly, recent studies also
suggested the critical cell cycle regulator pRB also plays a role
in cell size control, but in a differential manner as its role in cell
cycle regulation. It was shown that Rb triple knockout MEFs
(triple knockout MEFs lacking all three Rb family proteins
pRb, p107, and p130) have increased cell proliferation, but a
significantly reduced cell size compared with control MEFs
(Sage et al., 2000). It is interesting to note that FIP200 has been
reported to up-regulate RB1 expression in recent studies by
Chano and co-workers (Chano et al., 2002a; Kontani et al.,
2003), although it remains to be determined whether the pRB
pathway is involved in the regulation of cell size by FIP200.
Nevertheless, data presented in this study strongly suggest that
FIP200 regulates cell size through its interaction with the
TSC1–TSC2 complex.
Our previous study showed that FIP200 plays an impor-
tant role in cell proliferation; however, little is known about the
targets and molecular mechanisms by which FIP200 regulates
cell proliferation. Several studies also suggest the important role
of the TSC1–TSC2 complex in cell cycle control. Overexpres-
sion of TSC1 or TSC2 can inhibit cell cycle progression (Soucek
et al., 1998, 2001; Miloloza et al., 2000; Hengstschlager and
Rosner, 2003). TSC2 has been shown to interact with several
cell cycle regulators such as cdk1, cyclin A, and cyclin B (Cata-
nia et al., 2001). Furthermore, TSC2 was shown to stabilize p27
and negatively regulate cdk2 function (Soucek et al., 1998).
However, recent studies using TSC1 and TSC2 null MEFs
showed decreased proliferation (instead of increased prolifera-
tion as would be predicted from the overexpression studies)
compared with control MEFs (Y. Zhang et al., 2003). Further-
more, both TSC1 and TSC2 have been shown to be required for
serum stimulation of Akt activation, which plays critical roles
in cell proliferation and cell survival (Kwiatkowski et al., 2002;
Y. Zhang et al., 2003). Therefore, the function of TSC in the
regulation of cell proliferation is complicated. We initially hy-
pothesized that the interaction between FIP200 and the TSC1–
TSC2 complex would play a role in FIP200-mediated cell cycle
progression. However, we found that FIP200 can inhibit cell cy-
cle progression in TSC1 /  MEFs as well as control MEFs. In
addition, the FIP200 N1-638 segment does not interact with the
TSC1–TSC2 complex but still inhibits cell cycle progression.
Together, these data suggest that interaction between FIP200
and the TSC1–TSC2 complex is not involved in FIP200-medi-
ated cell cycle progression.
Our results demonstrated that FIP200 functions to posi-
tively regulate cell size and S6K phosphorylation. Although we
cannot exclude completely the possible role of other as yet
unidentified proteins that interact with FIP200, current evi-
dence suggests that these effects are through FIP200 interac-
tion with the TSC1–TSC2 complex. We found that association
of FIP200 or its segments N1-859 and N1-638 with the TSC1–
TSC2 complex correlated with their ability to increase cell size,
up-regulate S6K phosphorylation, and decrease TSC1–TSC
complex formation. Conversely, knockdown of endogenous
FIP200 by RNAi reduced S6K phosphorylation and cell size.
We also observed that FIP200 RNAi has no effect on S6K
phosphorylation in TSC1 knockdown cells but can decrease
S6K phosphorylation in control cells. Consistent with this,
FIP200 failed to stimulate S6K phosphorylation and increase
cell size in TSC1-null MEFs in contrast to control MEFs and
that the stimulatory effect in control MEFs was abolished by
rapamycin. These results suggested that the TSC1–TSC2 com-
plex and its downstream target mTOR are required for FIP200
regulation of S6K phosphorylation. Using both RNAi approach
and FAK /  cells, we showed that FIP200 inhibition of FAK
is not involved in the regulation of S6K phosphorylation by
FIP200.
Recent studies have established the TSC1–TSC2 com-
plex as a key regulator of cell size control, and rapid progress
has been made in delineating the downstream biochemical
pathways by which TSC regulates cell size as well as their
roles in the regulation of other cellular functions (Hengst-
schlager et al., 2001; Inoki et al., 2003b; Kwiatkowski, 2003;
Shamji et al., 2003). In contrast, relatively little is known about
the molecular mechanisms by which TSC is regulated by up-
stream regulators. Several proteins have been shown to interact
with TSC2 and thus regulate the TSC1–TSC2 complex func-
tion. Protein kinases AKT and AMPK have been identified to
phosphorylate TSC2 and negatively and positively regulate
TSC1–TSC2 complex function, respectively (Inoki et al., 2002,
2003b). 14-3-3 was shown to interact with and negatively regu-
late TSC2 without affecting TSC1–TSC2 interaction (Li et al.,
2002; Shumway et al., 2003). ERM family proteins and neu-
rofilament-light chain were shown to interact with TSC1, but it
is not clear whether these interactions regulate TSC1–TSC2
complex function (Lamb et al., 2000; Haddad et al., 2002).
Here, we identified a novel interaction between FIP200 and
TSC1 and provided evidence suggesting that this interaction
could negatively regulate TSC1–TSC2 complex function to in-
crease S6K phosphorylation and cell size. This is the first paper
suggesting a regulatory mechanism through protein interaction
with TSC1 of the complex.
Our results suggested that FIP200 is important for nutri-
ent stimulation-induced, but not energy- or serum-induced,
S6K activation (Fig. 9). Nutrient-induced S6K phosphorylation
was lower in FIP200 /  MEFs compared with FIP200 / 
MEFs as well as in 293T cells treated with FIP200 RNAi com-
pared with cells treated with control RNAi (Fig. 9, C and F).
However, we noted that the decrease was moderate in the
FIP200 /  MEFs, whereas it was greater in the short-term
RNAi knockdown experiments. This could be due to differ-
ences in the cells used in these two different sets of experi-
ments. Alternatively, FIP200 /  MEFs may have adapted to
the FIP200 null condition during the culture (thus becoming
less dependent on FIP200 for nutrient-induced S6K phosphory-
lation). However, we tested the expression levels of TSC1 and
TSC2 in these cells and found that their expression levels are
similar to those in FIP200 /  MEFs, suggesting that there is
no compensatory changes in either TSC1 or TSC2 expressionFIP200 INTERACTION WITH TSC1–TSC2 AND CELL SIZE REGULATION • GAN ET AL. 387
in the FIP200 / MEFs. Future studies will be necessary to
determine whether expression of other genes is altered, which
could partially compensate for the loss of FIP200 in nutrient-
stimulated S6K phosphorylation. Nevertheless, these results
suggest that FIP200 functions in the nutrient input to the
TSC1–TSC2 complex rather than being a general component
of the TSC1–TSC2 signaling pathway.
The molecular mechanisms by which FIP200 interaction
with TSC1 inhibits TSC1–TSC2 functions are not clear at
present. We found that overexpression of FIP200 reduced
TSC1–TSC2 complex formation (Fig. 8, A and B), raising the
possibility that FIP200 could inhibit TSC1–TSC2 function by
disrupting the complex formation. However, several consider-
ations would argue against such a possible mechanism. First,
knockdown of endogenous FIP200 by RNAi did not signifi-
cantly promote endogenous TSC1–TSC2 complex formation
(Fig. 8 C). Second, although our binding studies suggested that
TSC1 coiled-coil region mediates its interaction with TSC2
(unpublished data), the relevant functional segment of FIP200
(N1-859) does not contain its COOH-terminal coiled-coil re-
gion. Furthermore, the FIP200 binding region in TSC1 resides
in residues 403–787, which overlaps little with the putative
coiled-coil region of TSC1 (residues 719–998; also see Fig. 1
A). Thus, it is unlikely that FIP200 could disrupt TSC1–TSC2
interaction simply by its coiled-coil domain binding to the
coiled-coil region of TSC1 and displace TSC2 from its associa-
tion with TSC1. Lastly, we observed that FIP200 could coim-
munoprecipitate both endogenous (Fig. 1 E) and transfected
(Fig. 2 A) TSC2, which would not be possible if FIP200 func-
tioned to disrupt the complex by competing with TSC2 for
TSC1 binding. Although we cannot completely exclude the
possibility that FIP200 could function to reduce the TSC1–
TSC2 complex formation under some conditions, the afore-
mentioned consideration would suggest that FIP200 may in-
hibit TSC1–TSC2 complex function through mechanisms other
than disruption of the complex formation. It is possible that
FIP200 binding to TSC1 may also inhibit TSC1–TSC2 function
by inducing conformational change in TSC2 (indirectly through
TSC1) to inhibit its GAP activity toward Rheb. Future studies
will be necessary to investigate such a possible mechanism.
In summary, our studies identified FIP200 as a novel in-
teracting protein with TSC1 and suggested that FIP200 could
negatively regulate TSC function. These results indicate that,
in addition to its function in cell cycle progression, FIP200
also plays a role in cell size control. Furthermore, they provide
new insight into the molecular mechanism of TSC regulation.
These studies raise interesting implications regarding the mo-
lecular mechanisms by which cell proliferation and cell size
are coordinately regulated and, potentially, how dysregulation
of cell cycle progression and cell size control lead to diseases
such as cancer.
Materials and methods
Antibodies and reagents
The rabbit antiserum against FIP200 has been described previously (Abbi
et al., 2002). The polyclonal and monoclonal TSC1 antibodies were gifts
of V. Ramesh (Massachusetts General Hospital, Boston, MA). Affinity-puri-
fied antibody against GST was prepared from anti-GST serum using GST
immobilized on glutathione-Sepharose as an affinity matrix. The mouse
monoclonal   -vinculin antibody was obtained from Upstate Biotechnol-
ogy. The rabbit polyclonal  -HA (Y11) antibody, the mouse monoclonal
 -c-Myc-tag (9E10) antibody, rabbit polyclonal TSC2 antibody, rabbit
polyclonal  -FAK (C20) antibody, and rabbit polyclonal S6K antibody were
obtained from Santa Cruz Biotechnology, Inc. S6, Ser240/244 phospho-
S6, Thr389 phospho-S6K, Thr37/46 phospho-4E-BP1, Ser65 phospho-4E-
BP-1, and 4E-BP-1 antibodies were purchased from Cell Signaling Inc. Ra-
pamycin was obtained from Calbiochem. DPBS was purchased from Invitro-
gen. 2-Deoxy-D-Glucose (2-DG) was obtained from Sigma-Aldrich.
Yeast two-hybrid assays
The vector pLexA-FIP200 N1-859 was used to screen a human heart
MATCHMAKER LexA cDNA library ( 10
6 independent clones; gift from C.
Wu, University of Pittsburgh, Pittsburgh, PA). The yeast two-hybrid screen
was performed essentially as described previously (Tu et al., 1999).
Cell culture
The FIP200
 /  and control MEFs were isolated from E12.5 embryos. The
early passage (P1–P3) MEFs were used for studies here. The TSC1
 /  and
control MEFs were a gift of D. Kwiatkowski (Brigham and Women’s Hos-
pital, Boston, MA) and were maintained in DME supplemented with 10%
FBS as described previously (Kwiatkowski et al., 2002). The FAK
 /  fibro-
blasts derived from the FAK-null mouse embryos were a gift of D. Ilic (Uni-
versity of California, San Francisco, San Francisco, CA) and were main-
tained in DME supplemented with 10% FBS. 293T cells were cultured in
DME supplemented with 10% FBS. NIH3T3 cells were maintained in DME
supplemented with 10% CS.
Plasmid DNA construction
The vectors used in the yeast two-hybrid screen, pLexA, pLexA-Lamin C,
and pB42AD, have been described previously (Tu et al., 1999). pKH3-
FIP200 was used as a template to generate pLexA-FIP200 N1-859: the
PCR fragment amplified by primers 5 -gaattcatgaagttatatgtatttctgg-3  (for-
ward) and 5 -ctcgagtagtgttatttccagagaaca-3  (reverse) was first inserted
into pGEMT (BD Biosciences), then digested with XhoI and EcoRI, and the
fragment was then inserted into pLexA (BD Biosciences) digested with the
same enzymes to generate pLexA-FIP200 N1-859.
The mammalian cell expression vectors pKH3, pKH3-FIP200, and
pKH3- FIP200 N1-638 have been described previously (Abbi et al.,
2002). pKH3-FIP200 was used as a template to produce pKH3-FIP200
N1-859: the PCR product with primers 5 -cgcggatccatgaagttatatgtatttctgg-
3  (forward) and 5 -cccatcgattcatagtcttatttccagagaacattt-3  (reverse) was
digested with BamHI and ClaI. The fragment was then ligated to a linear-
ized pKH3 vector digested with the same enzymes. The same PCR product
was digested with BamHI and ClaI and then inserted into linearized pMAL
at the corresponding sites to generate pMAL-FIP200-N859, which is then
used to express MBP-N1-859 fusion protein from bacteria.
The expression vectors encoding HA-S6K, Flag-4EBP1, HA-TSC2,
GST-TSC2, Myc-TSC1, and Myc-TSC1 1–402 aa have been described
previously (Inoki et al., 2002, 2003a,b). Myc-TSC1 was used as template
to generate the following construct: the TSC1 789–1165 aa fragment was
amplified by primers 5 -cgcggatccgaattcgacaaccagagccaggaa-3  (for-
ward) and 5 -cccatcgatttagctgttttcatgatgagtctc-3  (reverse), digested with
BamHI and ClaI, and then inserted into linearized myc-tagged vector
pHAN digested with BamHI and ClaI, resulting in Myc-TSC1 789–1165
aa. The TSC1 403–787 aa fragment was amplified by primers 5 -cgcg-
gatccgatgactacgtgcacatttca-3  (forward) and 5 -cccatcgatctggctctggttgta-
gaatcc-3  (reverse), digested with BamHI and ClaI, and then inserted into
linearized myc-tagged vector pHAN digested with the same enzymes, re-
sulting in Myc-TSC1 403–787 aa. The same PCR product was digested
with BamHI and ClaI and then inserted into linearized pGEX2T at the cor-
responding sites to generate pGEX2T-TSC1 403–787 aa, which is then
used to express the GST-TSC1 403–787 aa fusion protein from bacteria.
The enzymes used in cloning were all obtained from New England Bio-
labs, Inc. Nucleotide sequences of all constructs were confirmed by DNA
sequencing.
Immunoprecipitation and Western blotting
Preparation of whole cell lysates, immunoprecipitation, and Western blot-
ting were performed as previously described (Abbi et al., 2002).
Preparation of GST, MBP fusion proteins, and in vitro binding assays
GST fusion proteins were produced and purified as described previously
(Abbi et al., 2002). MBP fusion proteins were purified according to theJCB • VOLUME 170 • NUMBER 3 • 2005 388
manufacturer’s instructions (New England Biolabs, Inc.). MBP and MBP-
N1-859 fusion proteins (10  g) were immobilized on amylose resin and
then incubated at 4 C with 2  g GST-TSC1 403–787 in binding buffer
(20 mM Tris, pH 8.0, 137 mM NaCl, 1 mM MgCl2, and 1% Triton X-100)
overnight at 4 C with rotation. The samples were then washed five times
with binding buffer, boiled in SDS buffer, resolved by SDS-PAGE, and an-
alyzed by Western blotting anti-GST antibody.
RNAi constructs and transfection
The RNAi vector pBS-U6 is a gift from Y. Shi (Harvard Medical School,
Boston, MA) and has been described previously (Sui et al., 2002). Con-
struction of RNAi vector was achieved in two separate steps: a 22-nt oligo
(oligo 1) was first inserted into the pBS-U6 vector digested with ApaI
(blunted) and HindIII. The inverted motif that contains the 6-nt spacer and
5 Ts (oligo 2) was then subcloned into the HindIII and EcoRI sites of the in-
termediate plasmid to generate pBS-U6-FIP200. For pBS-U6-FIP200 #7,
the sequence of oligo1 is 5 -GGAGATTTGGTACTCATCATCA-3  (for-
ward) and 5 -AGCTTGATGATGAGTACCAAATCTCC-3  (reverse); the se-
quence of oligo2 is 5 -AGCTTGATGATGAGTACCAAATCTCCCTTTTTG-
3  (forward) and 5 -AATTCAAAAAGGGAGATTTGGTACTCATCATCA-3 
(reverse). For pBS-U6-TSC1 #3, the sequence of oligo1 is 5 -GGGAGGT-
CAACGAGCTCTATTA (forward) and 5 -AGCTTAATAGAGCTCGTTGAC-
CTCCC-3  (reverse); the sequence of oligo2 is 5 -AGCTTAATAGA-
GCTCGTTGACCTCCCCTTTTTG-3  (forward) and 5 -AATTCAAAAAG-
GGGAGGTCAACGAGCTCTATTA (reverse). For pBS-U6-FAK #1, the se-
quence of oligo1 is 5 -GGCCAGTATTATCAGGCATGGA-3  (forward)
and 5 -AGCTTCCATGCCTGATAATACTGGCC-3  (reverse); the se-
quence of oligo2 is 5 -AGCTTCCATGCCTGATAATACTGGCCCTTTTTG-
3  (forward) and 5 -AATTCAAAAAGGGCCAGTATTATCAGGCATGGA-
3  (reverse). The RNAi targeting sequences were all analyzed by BLAST
search to ensure that they did not have significant sequence homology
with other genes.
For RNAi knockdown experiments, 293T cells grown in 6-well
plates were transfected with 1  g RNAi vectors and 50 ng HA-S6K con-
structs using Lipofectamine reagent (Invitrogen) in accordance with the
manufacturer’s instructions. For double knockdown experiments, 293T
cells were transfected with two RNAi vectors, each 500 ng, and 50 ng
HA-S6K constructs. To detect endogenous S6K phosphorylation, cells
grown in 6-well plates were transfected with 1  g RNAi vectors without
HA-S6K construct. After 3 d, growing cells were either directly lysed for
Western blotting or used for growth factor and nutrient stimulation experi-
ments as mentioned in the corresponding legends.
Cell size assay
To determine cell size and DNA content, FACS analysis with Cell Quest
software was performed as previously described (Inoki et al., 2003b).
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